

## **Troy Laboratories Pty Ltd**

Chemwatch: 5394-78 Version No: 3.1.1.1 Safety Data Sheet according to WHS and ADG requirements Chemwatch Hazard Alert Code: 2

Issue Date: 06/05/2020 Print Date: 07/05/2020 L.GHS.AUS.EN

## SECTION 1 IDENTIFICATION OF THE SUBSTANCE / MIXTURE AND OF THE COMPANY / UNDERTAKING

## Product Identifier

Product name         Ilium Medetomidine injection           Synonyms         APVMA number 64251; ACVM number A10488		
Relevant identified uses of the substance or mixture and uses advised against		
Relevant identified uses	For use as a sedative and analgesic in the restraint of cats and dogs. To be used as directed on product label.	

#### Details of the supplier of the safety data sheet

Registered company name	Troy Laboratories Pty Ltd		
Address	37 Glendenning Road Glendenning NSW 2761 Australia		
Telephone	02 8808 3600		
Fax	02 9677 9300		
Website	www.Troylab.com.au		
Email	admin@troylab.com.au		

## Emergency telephone number

Association / Organisation	Troy Laboratories Pty Ltd
Emergency telephone numbers	02 8808 3600 (Office hours (8am – 4pm, Monday to Friday))
Other emergency telephone numbers	Not Available

# **SECTION 2 HAZARDS IDENTIFICATION**

#### Classification of the substance or mixture

Hazard pictogram(s)

Poisons Schedule	S4			
Classification <sup>[1]</sup>	Reproductive Toxicity Category 2			
Legend:	1. Classified by Chernwatch; 2. Classification drawn from HCIS; 3. Classification drawn from Regulation (EU) No 1272/2008 - Annex VI			

Label elements



	spected of damaging fertility. Suspected of damaging the unborn child.			
	spected of damaging fertility. Suspected of damaging the unborn child.			
Precautionary statement(s) Prevention				
P201 Obtain special instructions before use.				
<b>P280</b> We	ear protective gloves/protective clothing/eye protection/face protection.			

#### r recattionary statement(s) response

P308+P313 IF exposed or concerned: Get medical advice/attention.

#### Precautionary statement(s) Storage

P405 Store locked up.

#### Precautionary statement(s) Disposal

P501 Dispose of contents/container to authorised hazardous or special waste collection point in accordance with any local regulation.

## **SECTION 3 COMPOSITION / INFORMATION ON INGREDIENTS**

#### Substances

See section below for composition of Mixtures

#### Mixtures

CAS No	%[weight]	Name
86347-15-1	<1	medetomidine hydrochloride
Not Available	balance	Ingredients determined not to be hazardous

#### **SECTION 4 FIRST AID MEASURES**

#### Description of first aid measures

Eye Contact	<ul> <li>If this product comes in contact with eyes:</li> <li>Wash out immediately with water.</li> <li>If irritation continues, seek medical attention.</li> <li>Removal of contact lenses after an eye injury should only be undertaken by skilled personnel.</li> </ul>
Skin Contact	<ul> <li>If skin contact occurs:</li> <li>Immediately remove all contaminated clothing, including footwear.</li> <li>Flush skin and hair with running water (and soap if available).</li> <li>Seek medical attention in event of irritation.</li> </ul>
Inhalation	<ul> <li>If fumes, aerosols or combustion products are inhaled remove from contaminated area.</li> <li>Other measures are usually unnecessary.</li> </ul>
Ingestion	<ul> <li>For advice, contact a Poisons Information Centre or a doctor at once.</li> <li>Urgent hospital treatment is likely to be needed.</li> <li>If swallowed do NOT induce vomiting.</li> <li>If vomiting occurs, lean patient forward or place on left side (head-down position, if possible) to maintain open airway and prevent aspiration.</li> <li>Observe the patient carefully.</li> <li>Never give liquid to a person showing signs of being sleepy or with reduced awareness; i.e. becoming unconscious.</li> <li>Give water to rinse out mouth, then provide liquid slowly and as much as casualty can comfortably drink.</li> <li>Transport to hospital or doctor without delay.</li> </ul>

#### Indication of any immediate medical attention and special treatment needed

Treat symptomatically.

Following recent ingestion or overdose of anxiolytic sedatives, hypnotics and neuroleptics, the stomach may be emptied by gastric lavage and aspiration. Patients should be managed with intensive symptomatic and supportive therapy with particular attention being paid to the maintenance of cardiovascular, respiratory and renal functions and to the maintenance of electrolyte balance.

MARTINDALE: The Extra Pharmacopoeia, 29th Edition

#### **SECTION 5 FIREFIGHTING MEASURES**

#### Extinguishing media

The product contains a substantial proportion of water, therefore there are no restrictions on the type of extinguishing media which may be used. Choice of extinguishing media should take into account surrounding areas.

Though the material is non-combustible, evaporation of water from the mixture, caused by the heat of nearby fire, may produce floating layers of combustible substances. In such an event consider:

- foam.
- dry chemical powder. carbon dioxide.

#### Special hazards arising from the substrate or mixture

Fire Incompatibility None known.			
Advice for firefighters			
Fire Fighting	<ul> <li>Alert Fire Brigade and tell them location and nature of hazard.</li> <li>Wear breathing apparatus plus protective gloves in the event of a fire.</li> <li>Prevent, by any means available, spillage from entering drains or water courses.</li> <li>Use fire fighting procedures suitable for surrounding area.</li> <li>DO NOT approach containers suspected to be hot.</li> <li>Cool fire exposed containers with water spray from a protected location.</li> <li>If safe to do so, remove containers from path of fire.</li> <li>Equipment should be thoroughly decontaminated after use.</li> </ul>		
Fire/Explosion Hazard	<ul> <li>The material is not readily combustible under normal conditions.</li> <li>However, it will break down under fire conditions and the organic component may burn.</li> <li>Not considered to be a significant fire risk.</li> <li>Heat may cause expansion or decomposition with violent rupture of containers.</li> <li>Decomposes on heating and may produce toxic fumes of carbon monoxide (CO).</li> <li>May emit acrid smoke.</li> </ul>		

May emit corrosive fumes.

HAZCHEM Not Applicable

## SECTION 6 ACCIDENTAL RELEASE MEASURES

## Personal precautions, protective equipment and emergency procedures

See section 8

## **Environmental precautions**

See section 12

#### Methods and material for containment and cleaning up

Minor Spills	<ul> <li>Clean up all spills immediately.</li> <li>Avoid breathing vapours and contact with skin and eyes.</li> <li>Control personal contact with the substance, by using protective equipment.</li> <li>Contain and absorb spill with sand, earth, inert material or vermiculite.</li> <li>Wipe up.</li> <li>Place in a suitable, labelled container for waste disposal.</li> </ul>
Major Spills	<ul> <li>Moderate hazard.</li> <li>Clear area of personnel and move upwind.</li> <li>Alert Fire Brigade and tell them location and nature of hazard.</li> <li>Wear breathing apparatus plus protective gloves.</li> <li>Prevent, by any means available, spillage from entering drains or water course.</li> <li>Stop leak if safe to do so.</li> <li>Contain spill with sand, earth or vermiculite.</li> <li>Collect recoverable product into labelled containers for recycling.</li> <li>Neutralise/decontaminate residue (see Section 13 for specific agent).</li> <li>Collect solid residues and seal in labelled drums for disposal.</li> <li>Wash area and prevent runoff into drains.</li> <li>After clean up operations, decontaminate and launder all protective clothing and equipment before storing and re-using.</li> <li>If contamination of drains or waterways occurs, advise emergency services.</li> </ul>

Personal Protective Equipment advice is contained in Section 8 of the SDS.

## SECTION 7 HANDLING AND STORAGE

#### Precautions for safe handling

Safe handling	<ul> <li>Avoid all personal contact, including inhalation.</li> <li>Wear protective clothing when risk of exposure occurs.</li> <li>Use in a well-ventilated area.</li> <li>Prevent concentration in hollows and sumps.</li> <li>DO NOT enter confined spaces until atmosphere has been checked.</li> <li>DO NOT allow material to contact humans, exposed food or food utensils.</li> <li>Avoid contact with incompatible materials.</li> <li>When handling, DO NOT eat, drink or smoke.</li> <li>Keep containers securely sealed when not in use.</li> <li>Avoid physical damage to containers.</li> <li>Always wash hands with soap and water after handling.</li> <li>Work clothes should be laundered separately. Launder contaminated clothing before re-use.</li> <li>Use good occupational work practice.</li> <li>Observe manufacturer's storage and handling recommendations contained within this SDS.</li> <li>Atmosphere should be regularly checked against established exposure standards to ensure safe working conditions are maintained.</li> </ul>
Other information	<ul> <li>Store in original containers.</li> <li>Keep containers securely sealed.</li> <li>Store in a cool, dry, well-ventilated area.</li> <li>Store away from incompatible materials and foodstuff containers.</li> <li>Protect containers against physical damage and check regularly for leaks.</li> <li>Observe manufacturer's storage and handling recommendations contained within this SDS.</li> </ul>

Conditions for safe storage, including any incompatibilities

Suitable container <ul> <li>Polyethylene or polypropylene container.</li> <li>Packing as recommended by manufacturer.</li> <li>Check all containers are clearly labelled and free from leaks.</li> </ul>		Packing as recommended by manufacturer.
	Storage incompatibility	None known

#### SECTION 8 EXPOSURE CONTROLS / PERSONAL PROTECTION

#### **Control parameters**

## OCCUPATIONAL EXPOSURE LIMITS (OEL)

INGREDIENT DATA

Not Available

## EMERGENCY LIMITS

Ingredient	Material name	TEEL-1	TEEL-2	TEEL-3
Ilium Medetomidine injection	Not Available	Not Available	Not Available	Not Available
Ingredient	Original IDLH	Revised IDLH		

#### Not Available Not Available medetomidine hydrochloride OCCUPATIONAL EXPOSURE BANDING Ingredient **Occupational Exposure Band Rating Occupational Exposure Band Limit** medetomidine hydrochloride F $\leq 0.01 \text{ mg/m}^3$ Occupational exposure banding is a process of assigning chemicals into specific categories or bands based on a chemical's potency and the Notes adverse health outcomes associated with exposure. The output of this process is an occupational exposure band (OEB), which corresponds to a range of exposure concentrations that are expected to protect worker health. MATERIAL DATA Exposure controls Engineering controls are used to remove a hazard or place a barrier between the worker and the hazard. Well-designed engineering controls can be highly effective in protecting workers and will typically be independent of worker interactions to provide this high level of protection. The basic types of engineering controls are: Process controls which involve changing the way a job activity or process is done to reduce the risk. Enclosure and/or isolation of emission source which keeps a selected hazard "physically" away from the worker and ventilation that strategically "adds" and "removes" air in the work environment. Ventilation can remove or dilute an air contaminant if designed properly. The design of a ventilation system must match the particular process and chemical or contaminant in use. Employers may need to use multiple types of controls to prevent employee overexposure. General exhaust is adequate under normal operating conditions. If risk of overexposure exists, wear SAA approved respirator. Correct fit is essential to obtain adequate protection. Provide adequate ventilation in warehouse or closed storage areas. Air contaminants generated in the workplace possess varying "escape" velocities which, in turn, determine the "capture velocities" of fresh circulating air required to effectively remove the contaminant. Type of Contaminant: Air Speed: 0 25-0 5 m/s solvent, vapours, degreasing etc., evaporating from tank (in still air) (50-100 f/min) aerosols, fumes from pouring operations, intermittent container filling, low speed conveyer transfers, welding, spray 0.5-1 m/s (100-200 drift, plating acid fumes, pickling (released at low velocity into zone of active generation) f/min.) Appropriate engineering direct spray, spray painting in shallow booths, drum filling, conveyer loading, crusher dusts, gas discharge (active 1-2.5 m/s (200-500 controls generation into zone of rapid air motion) f/min) grinding, abrasive blasting, tumbling, high speed wheel generated dusts (released at high initial velocity into zone of 2.5-10 m/s very high rapid air motion). (500-2000 f/min.) Within each range the appropriate value depends on: Lower end of the range Upper end of the range 1: Room air currents minimal or favourable to capture 1: Disturbing room air currents 2: Contaminants of low toxicity or of nuisance value only 2: Contaminants of high toxicity 3: Intermittent, low production 3: High production, heavy use 4: Small hood - local control only 4: Large hood or large air mass in motion Simple theory shows that air velocity falls rapidly with distance away from the opening of a simple extraction pipe. Velocity generally decreases with the square of distance from the extraction point (in simple cases). Therefore the air speed at the extraction point should be adjusted, accordingly, after reference to distance from the contaminating source. The air velocity at the extraction fan, for example, should be a minimum of 1-2 m/s (200-400 f/min.) for extraction of solvents generated in a tank 2 meters distant from the extraction point. Other mechanical considerations, producing performance deficits within the extraction apparatus, make it essential that theoretical air velocities are multiplied by factors of 10 or more when extraction systems are installed or used Personal protection Safety glasses with side shields. Chemical goggles. Contact lenses may pose a special hazard; soft contact lenses may absorb and concentrate irritants. A written policy document, describing the wearing of lenses or restrictions on use, should be created for each workplace or task. This should include a review of lens absorption Eye and face protection and adsorption for the class of chemicals in use and an account of injury experience. Medical and first-aid personnel should be trained in their removal and suitable equipment should be readily available. In the event of chemical exposure, begin eye irrigation immediately and remove contact lens as soon as practicable. Lens should be removed at the first signs of eye redness or irritation - lens should be removed in a clean environment only after workers have washed hands thoroughly. [CDC NIOSH Current Intelligence Bulletin 59], [AS/NZS 1336 or national equivalent] Skin protection See Hand protection below Wear chemical protective gloves, e.g. PVC. Hands/feet protection Wear safety footwear or safety gumboots, e.g. Rubber Body protection See Other protection below Overalls. P.V.C. apron. Other protection Barrier cream. Skin cleansing cream. Eve wash unit.

## Recommended material(s)

## GLOVE SELECTION INDEX

Glove selection is based on a modified presentation of the:

Type A Filter of sufficient capacity. (AS/NZS 1716 & 1715, EN 143:2000 & 149:2001, ANSI Z88 or national equivalent)

Respiratory protection

## "Forsberg Clothing Performance Index".

The effect(s) of the following substance(s) are taken into account in the *computer-generated* selection: llium Medetomidine injection

Material	CPI
BUTYL	С
NAT+NEOPR+NITRILE	С
NATURAL RUBBER	С
NATURAL+NEOPRENE	С
NEOPRENE	С
NEOPRENE/NATURAL	С
NITRILE	С
NITRILE+PVC	С
PE	С
PE/EVAL/PE	С
PVA	С
PVC	С
SARANEX-23	С
SARANEX-23 2-PLY	С
TEFLON	С
VITON	С
VITON/CHLOROBUTYL	С

\* CPI - Chemwatch Performance Index

A: Best Selection

B: Satisfactory; may degrade after 4 hours continuous immersion

C: Poor to Dangerous Choice for other than short term immersion

**NOTE:** As a series of factors will influence the actual performance of the glove, a final selection must be based on detailed observation. -

\* Where the glove is to be used on a short term, casual or infrequent basis, factors such as "feel" or convenience (e.g. disposability), may dictate a choice of gloves which might otherwise be unsuitable following long-term or frequent use. A qualified practitioner should be consulted.

#### SECTION 9 PHYSICAL AND CHEMICAL PROPERTIES

#### Information on basic physical and chemical properties

Selection of the Class and Type of respirator will depend upon the level of breathing zone contaminant and the chemical nature of the contaminant. Protection Factors (defined as the ratio of contaminant outside and inside the mask) may also be important.

Required minimum protection factor	Maximum gas/vapour concentration present in air p.p.m. (by volume)	Half-face Respirator	Full-Face Respirator
up to 10	1000	A-AUS / Class1	-
up to 50	1000	-	A-AUS / Class 1
up to 50	5000	Airline *	-
up to 100	5000	-	A-2
up to 100	10000	-	A-3
100+			Airline**

\* - Continuous Flow \*\* - Continuous-flow or positive pressure demand A(All classes) = Organic vapours, B AUS or B1 = Acid gasses, B2 = Acid gas or hydrogen cyanide(HCN), B3 = Acid gas or hydrogen cyanide(HCN), E = Sulfur dioxide(SO2), G = Agricultural chemicals, K = Ammonia(NH3), Hg = Mercury, NO = Oxides of nitrogen, MB = Methyl bromide, AX = Low boiling point organic compounds(below 65 degC)

- Cartridge respirators should never be used for emergency ingress or in areas of unknown vapour concentrations or oxygen content.
- The wearer must be warned to leave the contaminated area immediately on detecting any odours through the respirator. The odour may indicate that the mask is not functioning properly, that the vapour concentration is too high, or that the mask is not properly fitted. Because of these limitations, only restricted use of cartridge respirators is considered appropriate.
- Cartridge performance is affected by humidity. Cartridges should be changed after 2 hr of continuous use unless it is determined that the humidity is less than 75%, in which case, cartridges can be used for 4 hr. Used cartridges should be discarded daily, regardless of the length of time used

Appearance	Clear colourless liquid with no odour; mixes with water.		
Physical state	Liquid	Relative density (Water = 1)	1.004
Odour	Not Available	Partition coefficient n-octanol / water	Not Available
Odour threshold	Not Available	Auto-ignition temperature (°C)	Not Applicable
pH (as supplied)	5-6	Decomposition temperature	Not Available
Melting point / freezing point (°C)	~0	Viscosity (cSt)	Not Available
Initial boiling point and boiling range (°C)	~100	Molecular weight (g/mol)	Not Applicable
Flash point (°C)	Not Applicable	Taste	Not Available
Evaporation rate	Not Available	Explosive properties	Not Available
Flammability	Not Applicable	Oxidising properties	Not Available
Upper Explosive Limit (%)	Not Applicable	Surface Tension (dyn/cm or mN/m)	Not Available
Lower Explosive Limit (%)	Not Applicable	Volatile Component (%vol)	Not Available
Vapour pressure (kPa)	2.37 @20C	Gas group	Not Available
Solubility in water	Miscible	pH as a solution (1%)	Not Available
Vapour density (Air = 1)	Not Available	VOC g/L	Not Available

## SECTION 10 STABILITY AND REACTIVITY

Reactivity	See section 7
Chemical stability	Product is considered stable and hazardous polymerisation will not occur.
Possibility of hazardous reactions	See section 7
Conditions to avoid	See section 7
Incompatible materials	See section 7

# Page 6 of 8 **Ilium Medetomidine injection**

Hazardous decomposition products

# SECTION 11 TOXICOLOGICAL INFORMATION

See section 5

## Information on toxicological effects

Inhaled	The material is not thought to produce adverse health effects or irritation of the respiratory tract (as classified by EC Directives using animal models). Nevertheless, good hygiene practice requires that exposure be kept to a minimum and that suitable control measures be used in an occupational setting. Not normally a hazard due to non-volatile nature of product		
Ingestion	The material has <b>NOT</b> been classified by EC Directives or other classification systems as "harmful by ingestion". This is because of the lack of corroborating animal or human evidence. The material may still be damaging to the health of the individual, following ingestion, especially where pre-existing organ (e.g liver, kidney) damage is evident. Present definitions of harmful or toxic substances are generally based on doses producing mortality rather than those producing morbidity (disease, ill-health). Gastrointestinal tract discomfort may produce nausea and vomiting. In an occupational setting however, ingestion of insignificant quantities is not thought to be cause for concern.		
Skin Contact	Skin contact is not thought to have harmful health effects (as classified under EC Directives); the material may still produce health damage following entry through wounds, lesions or abrasions.		
Eye	Although the liquid is not thought to be an irritant (as classified by EC Directives), direct contact with the eye may produce transient discomfort characterised by tearing or conjunctival redness (as with windburn).		
Chronic	Exposure to the material may cause concerns for human fertility, generally on the basis that results in animal studies provide sufficient evidence to cause a strong suspicion of impaired fertility in the absence of toxic effects, or evidence of impaired fertility occurring at around the same dose levels as other toxic effects, but which are not a secondary non-specific consequence of other toxic effects, generally on the basis that results in appropriate animal studies provide strong suspicion of developmental toxicity in the absence of signs of marked maternal toxicity, or at around the same dose levels as other toxic effects but which are not a secondary non-specific consequence of other toxic effects.		
	TOXICITY	IRRITATION	
Ilium Medetomidine injection	Not Available	Not Available	
	ΤΟΧΙΟΙΤΥ	IRRITATION	
medetomidine hydrochloride	Oral (rat) LD50: 31 mg/kg <sup>[2]</sup>	Not Available	
	specified data extracted from RTECS - Register of 1		
MEDETOMIDINE HYDROCHLORIDE	performed with the S-isomer, dexmedetomidine. Det coli and Salmonella typhimurium) or the mammalian vitro human lymphocyte chromosome aberration tes clastogenic in the in vitro human lymphocyte chromo dexmedetomidine was clastogenic in an in vivo mou Fertility in male or female rats was not affected after maximum recommended human intravenous dose o mating and during mating in females. In an in-vitro h pregnant rat, placental transfer of dexmedetomidine foetal exposure should be expected in humans. Tera dexmedetomidine during the period of fetal organog	kmedetomidine was not mutagenic in cell forward mutation assay (mouse it with, but not without, rat S9 metabol psome aberration test with or without ise micronucleus test in NMRI mice, ti daily subcutaneous injections of dexi on a mcg/m2 basis) administered from uman placenta study, placental transi was observed when radiolabeled dexi atogenic effects were not observed in enesis (from gestation day 5 to 16) with human intravenous dose based on b	symphoma). Dexmedetomidine was clastogenic in the i ic activation. In contrast, dexmedetomidine was not human S9 metabolic activation. Although here was no evidence of clastogenicity in CD-1 mice. medetomidine at doses up to 54 mcg/kg (less than the 10 weeks prior to mating in males, and 3 weeks prior er of dexmedetomidine occurred. In a study in the rmedetomidine was administered subcutaneously. Thu rats following subcutaneous administration of ith doses up to 200 mcg/kg (representing a dose ody surface area) or in rabbits following intravenous
HYDROCHLORIDE	performed with the S-isomer, dexmedetomidine. Det coli and Salmonella typhimurium) or the mammalian vitro human lymphocyte chromosome aberration tes clastogenic in the in vitro human lymphocyte chromo dexmedetomidine was clastogenic in an in vivo mou Fertility in male or female rats was not affected after maximum recommended human intravenous dose of mating and during mating in females. In an in-vitro h pregnant rat, placental transfer of dexmedetomidine foetal exposure should be expected in humans. Terer dexmedetomidine during the period of fetal organog approximately equal to the maximum recommended administration of dexmedetomidine during the perior (representing approximately half the human exposur comparison). However, foetal toxicity, as evidenced subcutaneous dose of 200 mcg/kg. The no-effect do intravenous dose based on a body surface area com subcutaneously to pregnant rats at 8 and 32 mcg/kg on a body surface area comparison) from gestation of the 32 mcg/kg group were allowed to mate, elevan generation offspring.	xmedetomidine was not mutagenic in cell forward mutation assay (mouse) tt with, but not without, rat S9 metabol osome aberration test with or without ise micronucleus test in NMRI mice, th daily subcutaneous injections of dexi n a mcg/m2 basis) administered from uman placenta study, placental transf was observed when radiolabeled dex atogenic effects were not observed in enesis (from gestation day 5 to 16) w human intravenous dose based on b d of fetal organogenesis (from gestati re at the maximum recommended dos by increased post-implantation losses use in rats was 20 mcg/kg (representir nparison). In another reproductive tox (representing a dose less than the m day 16 through weaning, lower offspri ted foetal and embryocidal toxicity an	vitro , in either the bacterial reverse mutation assay (E. ymphoma). Dexmedetomidine was clastogenic in the in ic activation. In contrast, dexmedetomidine was not human S9 metabolic activation. Although here was no evidence of clastogenicity in CD-1 mice. medetomidine at doses up to 54 mcg/kg (less than the 10 weeks prior to mating in males, and 3 weeks prior to are of dexmedetomidine occurred. In a study in the semedetomidine was administered subcutaneously. Thus rats following subcutaneous administration of ith doses up to 200 mcg/kg (representing a dose ody surface area) or in rabbits following intravenous on day 6 to 18) with doses up to 96 mcg/kg se based on plasma area under the time-curve s and reduced live pups, was observed in rats at a ng a dose less than the maximum recommended huma icity study when dexmedetomidine was administered naximum recommended human intravenous dose based ing weights were observed. Additionally, when offspring d delayed motor development was observed in second
HYDROCHLORIDE Acute Toxicity	performed with the S-isomer, dexmedetomidine. Det coli and Salmonella typhimurium) or the mammalian vitro human lymphocyte chromosome aberration tes clastogenic in the in vitro human lymphocyte chromo dexmedetomidine was clastogenic in an in vito mou Fertility in male or female rats was not affected after maximum recommended human intravenous dose of mating and during mating in females. In an in-vitro h pregnant rat, placental transfer of dexmedetomidine foetal exposure should be expected in humans. Tera dexmedetomidine during the period of fetal organog approximately equal to the maximum recommended administration of dexmedetomidine during the period (representing approximately half the human exposur comparison). However, foetal toxicity, as evidenced subcutaneously to pregnant rats at 8 and 32 mcg/kg on a body surface area comparison) from gestation of the 32 mcg/kg group were allowed to mate, eleval generation offspring.	Armedetomidine was not mutagenic in a cell forward mutation assay (mouse it with, but not without, rat S9 metabol posome aberration test with or without ise micronucleus test in NMRI mice, th daily subcutaneous injections of dexion on a mcg/m2 basis) administered from numan placenta study, placental transf was observed when radiolabeled dea atogenic effects were not observed in enesis (from gestation day 5 to 16) w human intravenous dose based on b d of fetal organogenesis (from gestation re at the maximum recommended dos by increased post-implantation lossee use in rats was 20 mcg/kg (representin nparison). In another reproductive tox (representing a dose less than the m day 16 through weaning, lower offspri ted foetal and embryocidal toxicity an <b>Carcinogenicity</b>	vitro , in either the bacterial reverse mutation assay (E lymphoma). Dexmedetomidine was clastogenic in the in ic activation. In contrast, dexmedetomidine was not human S9 metabolic activation. Although here was no evidence of clastogenicity in CD-1 mice. medetomidine at doses up to 54 mcg/kg (less than the 10 weeks prior to mating in males, and 3 weeks prior fer of dexmedetomidine occurred. In a study in the smedetomidine was administered subcutaneously. Thus rats following subcutaneous administration of th doses up to 200 mcg/kg (representing a dose ody surface area) or in rabbits following intravenous on day 6 to 18) with doses up to 96 mcg/kg se based on plasma area under the time-curve a and reduced live pups, was observed in rats at a ng a dose less than the maximum recommended huma icity study when dexmedetomidine was administered aximum recommended human intravenous dose base- ing weights were observed. Additionally, when offspring d delayed motor development was observed in second
HYDROCHLORIDE Acute Toxicity Skin Irritation/Corrosion	performed with the S-isomer, dexmedetomidine. Descolar and Salmonella typhimurium) or the mammalian vitro human lymphocyte chromosome aberration tesc clastogenic in the in vitro human lymphocyte chromosome aberration tesc clastogenic in the in vitro human lymphocyte chromosome aberration tesc clastogenic in the in vitro human lymphocyte chromosome aberration tesc clastogenic in the in vitro human lymphocyte chromosome aberration tesc clastogenic in the in vitro human lymphocyte chromosome aberration tesc clastogenic in the in vitro human lymphocyte chromosome aberration at fected after maximum recommended human intravenous dose of mating and during mating in females. In an in-vitro hup regnant rat, placental transfer of dexmedetomidine foetal exposure should be expected in humans. Tera dexmedetomidine during the period of fetal organog approximately equal to the maximum recommended administration of dexmedetomidine during the period (representing approximately half the human exposur comparison). However, foetal toxicity, as evidenced subcutaneous dose of 200 mcg/kg. The no-effect do intravenous dose based on a body surface area comparison) from gestation of the 32 mcg/kg group were allowed to mate, elevar generation offspring.	Armedetomidine was not mutagenic in a cell forward mutation assay (mouse it with, but not without, rat S9 metabol posome aberration test with or without isse micronucleus test in NMRI mice, ti daily subcutaneous injections of dexi on a mcg/m2 basis) administered from uman placenta study, placental transf was observed when radiolabeled dore atogenic effects were not observed in enesis (from gestation day 5 to 16) with human intravenous dose based on bi d of fetal organogenesis (from gestation re at the maximum recommended dor by increased post-implantation losses use in rats was 20 mcg/kg (representin parison). In another reproductive tox 1 (representing a dose less than the m day 16 through weaning, lower offspri ted foetal and embryocidal toxicity an Carcinogenicity Reproductivity	vitro , in either the bacterial reverse mutation assay (E lymphoma). Dexmedetomidine was clastogenic in the i ic activation. In contrast, dexmedetomidine was not human S9 metabolic activation. Although here was no evidence of clastogenicity in CD-1 mice. medetomidine at doses up to 54 mcg/kg (less than the 10 weeks prior to mating in males, and 3 weeks prior fer of dexmedetomidine occurred. In a study in the smedetomidine was administered subcutaneously. Thu rats following subcutaneous administration of ith doses up to 200 mcg/kg (representing a dose ody surface area) or in rabbits following intravenous on day 6 to 18) with doses up to 96 mcg/kg se based on plasma area under the time-curve s and reduced live pups, was observed in rats at a ng a dose less than the maximum recommended huma icity study when dexmedetomidine was administered iaximum recommended human intravenous dose base ing weights were observed. Additionally, when offspring d delayed motor development was observed in second
HYDROCHLORIDE Acute Toxicity	performed with the S-isomer, dexmedetomidine. Det coli and Salmonella typhimurium) or the mammalian vitro human lymphocyte chromosome aberration tes clastogenic in the in vitro human lymphocyte chromo dexmedetomidine was clastogenic in an in vito mou Fertility in male or female rats was not affected after maximum recommended human intravenous dose of mating and during mating in females. In an in-vitro h pregnant rat, placental transfer of dexmedetomidine foetal exposure should be expected in humans. Tera dexmedetomidine during the period of fetal organog approximately equal to the maximum recommended administration of dexmedetomidine during the period (representing approximately half the human exposur comparison). However, foetal toxicity, as evidenced subcutaneously to pregnant rats at 8 and 32 mcg/kg on a body surface area comparison) from gestation of the 32 mcg/kg group were allowed to mate, eleval generation offspring.	Armedetomidine was not mutagenic in a cell forward mutation assay (mouse it with, but not without, rat S9 metabol posome aberration test with or without ise micronucleus test in NMRI mice, th daily subcutaneous injections of dexion on a mcg/m2 basis) administered from numan placenta study, placental transf was observed when radiolabeled dea atogenic effects were not observed in enesis (from gestation day 5 to 16) w human intravenous dose based on b d of fetal organogenesis (from gestation re at the maximum recommended dos by increased post-implantation lossee use in rats was 20 mcg/kg (representin nparison). In another reproductive tox (representing a dose less than the m day 16 through weaning, lower offspri ted foetal and embryocidal toxicity an <b>Carcinogenicity</b>	vitro , in either the bacterial reverse mutation assay (E lymphoma). Dexmedetomidine was clastogenic in the ii ic activation. In contrast, dexmedetomidine was not human S9 metabolic activation. Although here was no evidence of clastogenicity in CD-1 mice. medetomidine at doses up to 54 mcg/kg (less than the 10 weeks prior to mating in males, and 3 weeks prior fer of dexmedetomidine occurred. In a study in the rmedetomidine was administered subcutaneously. Thus rats following subcutaneous administration of th doses up to 200 mcg/kg (representing a dose ody surface area) or in rabbits following intravenous on day 6 to 18) with doses up to 96 mcg/kg se based on plasma area under the time-curve as and reduced live pups, was observed in rats at a ng a dose less than the maximum recommended huma icity study when dexmedetomidine was administered aximum recommended human intravenous dose base ing weights were observed. Additionally, when offspring d delayed motor development was observed in second

Data evaluable to make classification

# SECTION 12 ECOLOGICAL INFORMATION

Toxicity

	ENDPOINT TEST DURATION (H	R) SPECIES	VALUE SOURCE
llium Medetomidine injection	Not Not Available	Not Available	Not Not Available Available

	ENDPOINT TEST DURATION (HR)	SPECIES	VALUE SOURCE
medetomidine hydrochloride	Not Not Available	Not Available	Not Not Available Available
Legend:	Extracted from 1. IUCLID Toxicity Data 2. Europe ECHA Registered Substances - Ecotoxicological Information - Aquatic Toxicity 3. EPIWIN Suite V3.12 (QSAR) - Aquatic Toxicity Data (Estimated) 4. US EPA, Ecotox database - Aquatic Toxicity Data 5. ECETOC Aquatic Hazard Assessment Data 6. NITE (Japan) - Bioconcentration Data 7. METI (Japan) - Bioconcentration Data 8. Vendor Data		

DO NOT discharge into sewer or waterways.

#### Persistence and degradability

Ingredient	Persistence: Water/Soil	Persistence: Air
	No Data available for all ingredients	No Data available for all ingredients

#### Bioaccumulative potential

Ingredient	Bioaccumulation
	No Data available for all ingredients
Mobility in soil	
Mobility in soil	Mobility

#### SECTION 13 DISPOSAL CONSIDERATIONS

#### Waste treatment methods

#### **SECTION 14 TRANSPORT INFORMATION**

## Labels Required

Eabolo Roquilou		
Marine Pollutant	NO	
HAZCHEM	Not Applicable	

Land transport (ADG): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Air transport (ICAO-IATA / DGR): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Sea transport (IMDG-Code / GGVSee): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

Transport in bulk according to Annex II of MARPOL and the IBC code

Not Applicable

## SECTION 15 REGULATORY INFORMATION

#### Safety, health and environmental regulations / legislation specific for the substance or mixture

#### MEDETOMIDINE HYDROCHLORIDE IS FOUND ON THE FOLLOWING REGULATORY LISTS

Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 4

#### **National Inventory Status**

National Inventory	Status
Australia - AICS	No (medetomidine hydrochloride)
Canada - DSL	No (medetomidine hydrochloride)
Canada - NDSL	No (medetomidine hydrochloride)
China - IECSC	No (medetomidine hydrochloride)

Europe - EINEC / ELINCS / NLP	No (medetomidine hydrochloride)		
Japan - ENCS	No (medetomidine hydrochloride)		
Korea - KECI	No (medetomidine hydrochloride)		
New Zealand - NZIoC	Yes		
Philippines - PICCS	No (medetomidine hydrochloride)		
USA - TSCA	No (medetomidine hydrochloride)		
Taiwan - TCSI	No (medetomidine hydrochloride)		
Mexico - INSQ	No (medetomidine hydrochloride)		
Vietnam - NCI	No (medetomidine hydrochloride)		
Russia - ARIPS	No (medetomidine hydrochloride)		
Legend:	Yes = All CAS declared ingredients are on the inventory No = One or more of the CAS listed ingredients are not on the inventory and are not exempt from listing(see specific ingredients in brackets)		

## **SECTION 16 OTHER INFORMATION**

Revision Date	06/05/2020
Initial Date	30/04/2020

#### **SDS Version Summary**

Version	Issue Date	Sections Updated
3.1.1.1	06/05/2020	Ingredients, Supplier Information

#### Other information

Classification of the preparation and its individual components has drawn on official and authoritative sources as well as independent review by the Chemwatch Classification committee using available literature references.

The SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

#### Definitions and abbreviations

PC-TWA: Permissible Concentration-Time Weighted Average PC-STEL: Permissible Concentration-Short Term Exposure Limit IARC: International Agency for Research on Cancer ACGIH: American Conference of Governmental Industrial Hygienists STEL: Short Term Exposure Limit TEEL: Temporary Emergency Exposure  $\mathsf{Limit}_\circ$ IDLH: Immediately Dangerous to Life or Health Concentrations OSF: Odour Safety Factor NOAEL :No Observed Adverse Effect Level LOAEL: Lowest Observed Adverse Effect Level TLV: Threshold Limit Value LOD: Limit Of Detection OTV: Odour Threshold Value BCF: BioConcentration Factors BEI: Biological Exposure Index This document is copyright.

Apart from any fair dealing for the purposes of private study, research, review or criticism, as permitted under the Copyright Act, no part may be reproduced by any process without written permission from CHEMWATCH. TEL (+61 3) 9572 4700.